Huh. Who knew that there's a "formal dispute" process to the FDA.

I assume that the FDA is in charge of the appeal. I bet THAT's not biased in favor of the FDA, not one bit.

Quote:

---

Akebia Therapeutics has elected to not sit idly by after regulators rejected its chronic kidney disease med vadadustat earlier in the year, submitting a formal dispute request to the FDA.

In a complete response letter back in March, the agency had flagged safety concerns related to adjudicated blood clots and drug-induced liver injury. But Akebia pushed back last month, sending across a formal dispute request that defended vadadustat as a potential treatment for anemia due to chronic kidney disease in adult patients on dialysis.

---